Each year, the ATS Educational and the International Conference committees collaborate to ensure that International Conference symposia are eligible for Maintenance of Certification points.
ATS 2019 attendees are able to earn up to 54.5 American Board of Internal Medicine MOC Medical Knowledge points and 20 American Board of Pediatrics Part 2 MOC Self-Assessment points.
In addition to the adult and pediatric Core Curriculum there are 26 symposia that are eligible for MOC and will cover adult pulmonary, critical care, and sleep medicine as well as pediatric pulmonary symposia. The Adult and Pediatric Symposia eligible for MOC at the conference can be found at http://conference.thoracic.org/program/moc.php.
How to Earn MOC Points at ATS 2019
During ATS 2019: Attend any or all of the MOC symposia you are interested in. These sessions will be highlighted in the Final Program.
After ATS 2019: Take the post-session test. All the tests are available on Wednesday, May 22, 2019, 4 p.m. CST and attendees can take the tests at no cost through July 31, 2019. Please note: audience response during a session does not count at the post-test.
How to Earn CME ATS 2018
There are two separate pathways for claiming MOC and CME. In order to claim both CME and MOC you will need to follow steps for both. You must pass the MOC post- test to earn MOC and complete the CME evaluation to claim CME. Claiming one will not automatically transfer to the other.
The following MOC symposia have received educational grant support.
A82 – “Cystic Fibrosis: Heterogeneity in a Monogenetic Disease”
Educational Grant Support: Vertex Pharmaceuticals, Inc.
CC1 – “Pulmonary Clinical Core Curriculum I”
Educational Grant Support: Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals
B1 – “Clinical Year in Review 2”
Educational Grant Support: Genentech, Inc., GlaxoSmithKline, Insmed, Inc., Mallinckrodt Pharmaceuticals, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals
B8 – “Ensuring Broad Dissemination and Equitable Access to Lung Cancer Screening: Challenges and Opportunities”
Educational Grant Support: AstraZeneca LP, Genentech, Inc.
CC3 – “Pulmonary Clinical Core Curriculum II”
Educational Grant Support: Genentech, Inc., GlaxoSmithKline, Insmed, Inc., Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals
C1 – “Clinical Year in Review 3”
Educational Grant Support: Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc.
C7 – “Pulmonologists Need to Know About Cancer Immunotherapy”
Educational Grant Support: AstraZeneca LP, Genentech, Inc.
C9 – “Difficult to Treat Asthma in the Pediatric Population”
Educational Grant Support: Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals
C82 – “Challenges in the Long-Term Clinical Management of Sarcoidosis”
Educational Grant Support: Boehringer Ingelheim Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals
D1 – “Clinical Year in Review 4”
Educational Grant Support: Actelion Pharmaceuticals US, Inc., AstraZeneca LP, Bayer US, Genentech, Inc., United Therapeutics Corporation